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INTRODUCTION
ADR monitoring and reporting helps in detection and 
prevention of reoccurrence of ADRs. The objective of 
this study was to conduct ADR reporting in department of 
General Medicine, Government Medical College, Jagdalpur, 
Chhattisgarh, India.
According to WHO’S definition an Adverse Drug 
Reaction (ADR) is a response to a drug that is noxious and 
unintended and occurs at doses normally used in human 
for the prophylaxis, diagnosis, and treatment of disease, or 
for modification of physiological function.[1,2]
The factors such as polypharmacy, age, gender, race, 
genetics, multiple, and inter-current diseases can cause 
morbidity and mortality. Lazarous et al. estimated that 
ADRs were the fourth to sixth largest cause of death in the 
United States.[3] In United Kingdom most of the studies 
were performed in the previous two decades and were 
restricted to specific areas such as monitoring of ADRs 
in geriatric patients.[4-11] The largest UK study was based 
on retrospective review of case reports and gave poor 
documentation.[12]
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The aim of the present study was to observe adverse drug reactions (ADRs) with respect to polypharmacy at 
tertiary care centre at Bastar, Jagdalpur (Government Medical College, Jagdalpur). A prospective, observational 
evaluation of the ADRs conducted over a period of 6 months in Department of Medicine in Government Medical 
College, Jagdalpur. During the study period, a total of about 4850 patients visited the OPD and inpatient ward 
of medicine department, and 154 ADRs events were reported. Out of 154 reports that were identified, a higher 
percentage of ADRs in females (51.29%) was observed as compared to males (48.7%). Of the 154 ADRs, 
76 (49.35%) were found to be mild, 55 moderate (35.71%), and 23 severe (14.93%). A total of 99 (64.28%) 
ADRs were observed in patients receiving four or more medications concurrently. Conversely 55 (35.71%) 
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The detection of adverse drug reactions (ADRs) has 
become increasingly significant because of introduction of 
a large number of potent toxic chemicals as drugs in the 
last two or three decades. WHO has intervened seriously 
in this matter and established an international adverse drug 
reactions monitoring centre at Uppsala, Sweden, which is 
collaborating with national monitoring centers in around 
70 countries.[1]
In many countries, drug utilization studies have been 
performed by means of prescription databases, such as 
the Tayside database in Scotland,[13] the VAMP database 
in England,[14] the Saskatchewan database in Canada,[15] the 
Compass and the Kaiser Permanente databases in USA,[16] 
and the Pharma database in the Netherlands.[17] Generally, 
prescription databases have proved their value as powerful 
research tools for a multitude of pharmacoepidemiological 
studies, and studies comparing drug exposure according 
to different sources have demonstrated registered data as 
one of the most accurate sources of data.
As per the ADR monitoring in our country, very little 
attention has been given so far and very few original studies 
have been done in this regard. We have very few ADR 
monitoring centers right now and lot of efforts is required 
in order to collect ADR data which may generate safety 
surveillance of billions of therapeutically active substances 
either alone or in combinations.
Avoidable adverse effects will be reduced by more skilful 
prescribing and this means that doctors, among all the 
other claims on their time, must find time to understand 
drugs better, as well as to understand their patients and 
their diseases.[18]
Taking this view in mind we would like to strengthen the 
ADR monitoring and spreading awareness among our 
clinicians, we performed a prospective, observational analysis 
of ADRs caused by medicines prescribed in the department 
of Medicine with the help of department of Pharmacology 
in Government Medical College, Jagdalpur to identify 
problem prevalence and to assess causality of these reactions.
MATERIALS AND METHODS
Study of ADR monitoring was prospective, observation study 
done from July 2008 to December 2008 over six month’s 
duration in Medicine department with help of department 
of Pharmacology. An informed consent was taken from 
the patients who experienced ADRs for participating in the 
study. The study was initiated after the approval of the study 
protocol by Institutional Review Board.
Inclusion criteria
The inclusion criteria of this study were all the suspected 
ADRs that may be due to the medications, both prescribed 
and over the counter, taken by patients either as inpatients 
or outpatients, that were ultimately noted and reported.
Exclusion criteria
•  The use of alternative system of medicines like 
Ayurveda, Homeopathy, Unani, etc.
•  Over prescribing, over dosage, and excess consumption
•  Patients taking more than ten prescription drugs
•  All mentally retarded
•  Drug addicts
•  Unconscious and patients unable to respond to verbal 
questions were also excluded from the study.
Preparation of  adverse drug reaction reporting forms (yellow cards)
Yellow cards were prepared which included all the relevant 
data such as name of the patient, age, sex, height, weight, 
date of occurrence of events, brief description of the 
reaction, name of the suspected drug causing the reaction, 
duration of reaction, and name of the clinician reporting 
the reaction on the basis of WHO guidelines.
Collection of data
Upon receiving the report, investigator visited the respective 
ward or the department and collected the necessary details. 
When an ADR was suspected, the data from the patient 
profile form such as patient details, patient medication 
details including non-prescription drugs, alternative 
treatments and recently ceased medications, comprehensive 
adverse reaction details including description of the 
reaction, time of onset and duration of the reaction and 
treatment given with relevant investigation reports were 
collected.
Causality and severity assessment: The causality was assessed 
by using Naranjo causality assessment scale and the severity 
was assessed by using the Hartwig severity assessment scale 
according to the recommendation by the WHO Uppsala 
Monitoring Center.[12] Data extracted independently by two 
investigators were analyzed by a random-effects model. To 
obtain the overall incidence of ADRs in hospitalized patients, 
we combined the incidence of ADRs occurring while in 
the hospital plus the incidence of ADRs causing admission 
to hospital. We excluded errors in drug administration, 
noncompliance, overdose, drug abuse, therapeutic failures, 
and possible ADRs. Serious ADRs were defined as those 
that required hospitalization, were permanently disabling, or J Young Pharm Vol 2 / No 1  97
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resulted in death. To confirm adverse drug reactions, if some 
investigations were required, they were carried out with the 
consent of the concerned physician.
Statistical method
From pooled data we calculated mean, standard deviation, 
percentage, and as required the Chi-squared (x2) test were 
applied to find the association between outcome and 
parameters and P-values less than 0.05 were considered 
as significant.
RESULTS
During the 6 months study period, a total 4850 patients 
visited the medicine OPD and inpatients. The demographic 
data is as follows; among 4850 patients 3150 were in age 
group of less than 35 years and 1700 in age group of more 
than 35 years [Table 1]. Total male subjects were 2986 and 
females were 1864. A total of 154 ADRs (3.17%) were 
reported in 4850 patients.
The gender distribution among the patients, who experienced 
ADRs were 75 (48.71%) males and 79 (51.29%) females. 
Taking the whole study population (4850) females (1864) 
have experienced more number of ADRs as compared to 
the male (2986) population. Similarly, among 4850 study 
population, 3150 were less than 35 years and 1700 patients 
were more than 35 years age group, and they had 84 patients 
(54.55%) and 70 patients (45.5%) with ADRs, respectively. 
Their statistical significance is shown in Table 2.
As expected, Polypharmacy had a major influence on the 
occurrence of ADRs with a total of 99 (64.28%) ADRs 
observed in patients receiving four or more medications 
concurrently [Table 3]. Conversely, 55 (35.71%) ADRs 
were detected in patients on three or less medicines. The 
frequency of ADRs associated with different routes of 
administration was as follows: Oral (n 5 135), parentral 
(n 5 16), and topical (n 5 3) [Table 4].
The gastrointestinal side effects (e.g. gastritis, dysphasia, etc.) 
were at the top with 39.61% followed by skin, and 
subcutaneous disorders (28.57%). Other main groups were 
respiratory 17 (11.03%), CNS and neurological disorders 
(8.44%). The detailed description of organ systems affected 
by ADRs is shown in Table 5.
Out of a total number of 154 ADRs, 15 (9.74%) 
were classified as certain, e.g. hypersensitivity reaction 
with intravenous contrast medium, skin reaction with 
cefotaxime injection, itching and dermatitis with 
etophylline tablets, and hypoglycemia with glibenclamide 
tablets. 56 ADRs (36.36%) were considered probable e.g. 
dry cough with enalapril and dysphasia with furosemide 
tablets. 48 (31.16%) were classified as possible e.g. loss 
of appetite and pain in abdomen with antitubercular 
medicines and breathlessness with nimesulide and 
metoprolol. 15 ADRs (9.74%) could not be categorized 
and were placed under unassessable category e.g. itching 
with antitubercular drugs and mental depression with 
metoprolol [Table 6].
Out of the 154 ADRs, 76 (49.35%) were found to be mild 
e.g. cold extremities with atenolol, 55 (35.71%) moderate 
e.g. dry cough with ramipril, and 23 (14.93%) severe e.g. 
subcutaneous bleeding with carbimazole. Most of the 
severe ADRs were associated with antitubercular, oral 
hypoglycemic drugs, insulin, and heparin. These were 
reported more commonly with injectables as compared 
to oral medications. Ten serious and life-threatening 
ADRs were also reported e.g. hepatitis with antitubercular 
medicines and anaphylactic reactions with iopromide 
(i.v. contrast medium). Drug-induced morbidity is an 
important cause of hospitalization and is associated with 
significant mortality. Most of the ADRs observed in our 
study were either mild or moderate [Table 7].
Table 1: Demographic data of patients who had adverse 
drug reactions
Demographic parameter No. of ADRs (%)
Age wise
,35 years 84 (54.5)
.35 years 70 (45.45)
Sex wise
Male 75 (48.71)
Female 79 (51.29)
Table 2: Statistically significant correlation of adverse drug reactions with age and sex of patients
Demographic data Total no. of patient’s in study No. of patients with ADRs (%) Chi-square test result
Age
,35years 3150 84 (54.55) P 5 0.006 , 0.05 significant
(with df 5 1, and confidence 
level 5 95%)
.35 years 1700 70 (45.5)
Total 4850 154
Sex
Male 2986 75 (48.71) P 5 0.001 , 0.05 significant
(with df 5 1, and confidence 
level 5 95%)
Female 1864 79 (51.29)
Total 4850 15498   J Young Pharm Vol 2 / No 1
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Distribution of ADRs across therapeutic classes was 
as follows: Antimicrobials (28.57%), antihypertensives 
(24.02%), antidiabetics (14.28%), and NSAIDs (9.74%) 
[Table 8]. Among the individual drugs, ramipril was 
associated with maximum cases of ADRs (6.6%) 
followed  by  amlodipine  (5.7%)  and  atenolol 
(4.1%). In case of fixed dose drug combinations, 
isoniazid 1 rifampicin 1 ethambutol 1 pyrazinamide 
combination was responsible for 13.1% ADRs.
The statistical significant difference was observed as more 
ADR found in age group of more than 35 years and more 
ADR in female subjects as compared to age group less than 
35 years and male subjects, respectively [Table 2].
DISCUSSION
World Health Organization (WHO) under the Pharma 
covigilance program recruited about 78 countries as its 
members.[19,20] Most of these member countries have a 
well-established ADR reporting system and primarily 
doctors are given responsibility to report ADRs. In India, 
the National Pharmacovigilance Program (NPP) encourages 
the doctors and hospital pharmacists to report ADRs.
The primary objective was to estimate the prevalence 
of the ADR; in secondary objective we examined the 
different factors that influence the outcome such as 
age, sex, the effect of Polypharmacy, and effects of route 
of administration of drugs.
Although female population had more prevalence of 
ADRs, the difference was significant with respect to the 
male population. Previous studies also reported that the 
occurrence of ADRs is more common in women.[21] this 
finding may be because of the differences in weight and 
body mass index, hormonal changes unique to females 
(during puberty, menstrual cycles, menopause), and the 
effect of these changes on drug metabolism. Other possible 
factors include differences in fat composition (with respect 
to impact on drug distribution) and genomic constitutional 
differences influencing the levels of various enzymes 
involved in drug metabolism.[22,23]
In another study, Gor et al. showed overall 3% ADR, 
and similar to our study majority of ADRs were due to 
chemotherapeutic agents but in their study on sex of the 
patients did not influence the incidence rate of ADR, as 
in our study females were more prone to ADR.[24] In other 
Table 3: Number of drugs and adverse drug reactions (%)
No. of drugs No. of ADRs (%) (%)
1 14 (9.09) 55 (35.71)
2 14 (9.09)
3 27 (17.53)
4 22 (14.28) 99 (64.28)
5 32 (20.78)
6 20 (12.99)
7 25 (16.23)
Total 154
Table 4: Adverse drug reaction related to route of drug 
administration
Route ADRs (%)
Oral 135 (87.66)
Parentral 16 (10.39)
Topical (local) 3 (1.95)
Total 154
Table 5: Adverse drug reaction and organ system involved
Organ system involved No. of ADRs (%)
Gastrointestinal disorders 61 (39.61)
Skin, mucous membrane 44 (28.57)
Respiratory disorders 17 (11.03)
CNS and neurological disorders 13 (8.44)
Blood and lymphatic system 5 (3.25)
Hepato-billiary disorders 2 (1.29)
Others 12 (7.79)
Totals 154
Table 7: Classification of adverse drug reactions on the 
basis of severity
Severity No. of ADRs (%)
Mild 76 (49.35)
Moderate 55 (35.71)
Severs 23 (14.93)
Total 154
Table 6: Causality assessment of adverse drug reactions
Probability scale No. of ADRs (%)
Certain 15 (9.74)
Probable 56 (36.36)
Possible 48 (31.16)
Unlikely 08 (5.19)
Conditional 12 (7.79)
Un-assessable 15 (9.74)
Total 154
Table 8: Pharmacological classes of drugs implicated to 
cause adverse drug reactions
Drug classes No. of ADRs (%)
Antimicrobials 44 (28.57)
Antihypertensive 34 (24.02)
Anti-diabetics 22 (14.28)
NSAID 15 (9.74)
Blood and blood products 14 (9.09)
CNS drugs 11 (7.14)
Anticoagulants 6 (3.89)
Others 8 (5.19)
Total 154J Young Pharm Vol 2 / No 1  99
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study by Rajan et al., 0.22% ADR were reported which is 
very low as compared to our (3.17%) while rest of their 
finding are similar to our study.[25]
In our study, the majority of ADRs were in .35 years 
age group. The reasons that could be attributed are that 
the patients of this age group suffered from hypertension 
and diabetes. So this age group used more number of 
medicines and frequently visited the medicine OPD for 
their regular check-up and complained about drug-related 
adverse events, though most of these adverse events were 
mild and easily tolerated.
A majority of the ADRs were associated with oral 
administration of medicines followed by parenteral route. 
Most of the ADRs with injectable medications were 
severe. The three topical reactions observed was erythema 
(localized skin redness) on application of heparin sodium 
cream. Gastrointestinal ADRs were most commonly 
observed with oral medications.
The incidence of adverse drug events is directly proportional 
to the number of drugs being taken and increases 
remarkably as number of drugs rises. Many epidemiological 
studies of risk factors for adverse drug reactions have 
shown that the number of concurrently used drugs is 
the most important predictor of these complications.[26] 
Polypharmacy needs to be discouraged as a good number 
of ADRs results from drug-drug interactions.
Both hypertensive and diabetic patients are predisposed to 
ADRs as in our study and they are at inevitable risk of bad 
effects of drugs due to sub-optimal functionality of their 
organ systems. This necessitates careful organ function 
analysis prior to prescription writing for any medication. 
One of the essential reasons of wide prevalence of ADRs 
in hypertensive and diabetic patients is that they are elderly 
and are often on multiple-drug therapy.
In our study, we found gastrointestinal side effects 
(e.g.  gastritis, dysphagia, etc.) at the top of the list of 
ADRs followed by skin and subcutaneous disorders. 
Next main groups are metabolic, nutritional, CNS, 
and neurological disorders. Neurological ADRs were 
at the top of the list of ADRs in previous studies, and 
gastrointestinal ADRs were reported among the top three 
groups of ADRs.[27,28]
The present study is done on quite a large number of 
subjects over a prolong period but the limitations were the 
loss of subjects during follow up and the low awareness 
of subjects and unintentional ignorance of adverse effects 
by the treating physician which may be the reason for the 
low ADR prevalence (3.17%).
The major controversy arising from this study is pointing 
toward the part of both parties: Patient and physician, 
the patients being unaware of the ADRs. In our hospital 
and other health care facilities, the documentation of 
ADRs is getting unintentionally missed which could be 
because of technical or shortage of staff or lack of proper 
sensitization, and many a times the mortality and morbidity 
associated with ADR are taken as outcome of disease 
processes itself.
CONCLUSION
The present work is the maiden pharmacovigilance study 
conducted at our teaching hospital. It has provided baseline 
information about the prevalence of ADRs and their 
distribution among different age groups, genders, organ 
systems affected, and therapeutic classes of medicines. The 
data presented here will be useful in future, long term and 
more extensive ADR monitoring in the hospital and will 
be useful in framing policies towards rational use of drugs.
There is a need to inform the treating doctors about the 
importance of observing for ADR following pharma 
cotherapy, recording them meticulously, and reporting them 
to the concerned authority. This practice will prove to be 
very valuable in making the drug therapy safer and rational.
So in future a comprehensive sensitization Programme 
is required in each step of health care system right from 
treating doctors, nurses, paramedics, and drug dispensing 
pharmacist to ensure better and safe pharmacotherapy and 
improve compliance of patients.
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